secwatch.observer — SEC 8-K summary
======================================

Issuer:     CATALYST PHARMACEUTICALS, INC. (CPRX)
CIK:        0001369568
Form:       8-K
Filed at:   2023-11-03T23:59:59+00:00
Accession:  0001193125-23-270432
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Catalyst Pharma receives two new US patent allowances for FIRDAPSE, extending IP protection to mid-2032
--------------------------------------------------------------------------------

- USPTO allowed two patents covering FIRDAPSE bioavailability under fasting/fed conditions; expected grant within two months.
- Patents expire mid-2032; will be listed in FDA Orange Book, raising total listed patents to eight.
- CEO states patent exclusivity in US until 2037; these new patents strengthen IP estate.
- FIRDAPSE is only approved US treatment for Lambert-Eaton myasthenic syndrome.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1369568/000119312523270432/0001193125-23-270432-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1369568/000119312523270432/d583587d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-270432

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer